Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.

× No keyword cloud information.

11 in total

1. Improving symptom control in early Parkinson's disease.

Authors: Stuart H Isaacson; Robert A Hauser
Journal: Ther Adv Neurol Disord Date: 2009-11 Impact factor: 6.570

2. Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.

Authors: Eldo V Kuzhikandathil; Samantha Cote; Soumava Santra; Aloke K Dutta
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-11-20 Impact factor: 3.000

3. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.

Authors: Banibrata Das; Subramanian Rajagopalan; Gnanada S Joshi; Liping Xu; Dan Luo; Julie K Andersen; Sokol V Todi; Aloke K Dutta
Journal: Neuropharmacology Date: 2017-05-19 Impact factor: 5.250

4. D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model.

Authors: Soumava Santra; Liping Xu; Mrudang Shah; Mark Johnson; Aloke Dutta
Journal: ACS Chem Neurosci Date: 2013-08-20 Impact factor: 4.418

Review 5. Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors: Thomas Müller
Journal: Drugs Date: 2015-02 Impact factor: 9.546

Review 6. alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors: Kathleen A Maguire-Zeiss
Journal: Pharmacol Res Date: 2008-09-16 Impact factor: 7.658

Review 7. The Human Experience with Intravenous Levodopa.

Authors: Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal: Front Pharmacol Date: 2016-01-06 Impact factor: 5.810

Review 8. Safinamide: an add-on treatment for managing Parkinson's disease.

Authors: Thomas Müller
Journal: Clin Pharmacol Date: 2018-04-05

9. Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson's disease with dementia.

Authors: Deepthi Yedlapudi; Liping Xu; Dan Luo; Gregory B Marsh; Sokol V Todi; Aloke K Dutta
Journal: Sci Rep Date: 2019-12-23 Impact factor: 4.379

Review 10. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

Authors: Gennaro Pagano; Tayyabah Yousaf; Marios Politis
Journal: Curr Neurol Neurosci Rep Date: 2017-10-03 Impact factor: 5.081